Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRISPR-Edited Donor Kidneys in Renal Transplant
NCT07053462Phase 2Recruiting
- Sponsor
- American Organ Transplant and Cancer Research Institute
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in end stage renal disease (ESRD), sponsored by American Organ Transplant and Cancer Research Institute. Primary endpoints: Incidence of Treatment-Related Serious Adverse Events at 1 year and Graft Survival at 6 Months. Started Jun 2025; status: recruiting.
02
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT07053462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053462.